In August 2005 the Viennese agency PR&D will start an extensive program of Public Awareness measures, together with representatives from the Campus Vienna Biocenter.
Vienna, June 13: In August 2005 the Viennese agency PR&D will start an extensive program of Public Awareness measures, together with representatives from the Campus Vienna Biocenter. The aim of the program is to give a wide range of target groups in the public a better understanding of research and development on site. The activities, which are of great societal importance, are being made possible by financial support from the Austrian Council for Research and Technology Development in the amount of EUR 140.000.
Under the co-ordination of the Viennese agency PR&D - Public Relations for Research & Development, a public relations offensive has started at the Campus Vienna Biocenter which will continue for 18 months. The basis of these measures lies in the successful co-operation of PR&D, the Campus Vienna Biocenter Association and dialoggentechnik. Through the initiative of Dr. Till C. Jelitto, managing director of PR&D, the consortium has created a communication-concept which was submitted to the program "Innovatives sterreich" for support. The aim of this program, which is supported by three ministries - the Federal Ministry of Transport, Innovation and Technology (BMVIT), the Federal Ministry of Education, Science and Culture (BMBWK) and the Federal Ministry of Business and Labor (BMWA) - and the Austrian Council for Research and Technology Development (RFTE), is to inform the public of the benefits of research.
Michael Binder, managing director of the RFTE (since June director "Strategy" FFG) , explains the council's decision to support the realization of the concept with 75% of the total expenses as follows: "There was an extremely good response to the latest request for proposals from the program Innovative Austria, with more than 88 applications. This is proof of the scientific community's growing responsiveness regarding the necessity for communicating the benefits of research and technology. Unfortunately we could only support the very best ideas. Among these was the application from the group at the Campus Vienna Biocenter. This group projected, with great commitment, a concept of worthy measures which convey the value of biotechnology in society in a fascinating and efficient way to several target groups." Further financial support for the realization of this idea has been secured by the three participating organisations themselves.
Made-to-Measure Measures
Central to the communication-strategy of the 1000 scientists of 16 organisations resident at the Campus, is the implementation of the measures in two subprograms which makes it possible to address different parts of the public on various levels. The subprogram "Research with Fun" will address young persons and adults, who to begin with are less involved with biotechnology, on an emotional-playful basis. The subprogram "Research for Us" makes contact to groups of the public, who already have an interest, on a rational and factual level. The two programs specifically consist of three packages of measures to be taken. For the subprogram entitled "Research with Fun" they are:
A complementary exhibition will serve to present the "works of art" of the two measures to the public. An introduction to the initial inspiring experiment will open the exhibition.
The subprogram "Research for Us" consists of the following three packages of measures:
Concerning the extensive program, Dr. Gertraud Unterrainer, Chairperson of the Campus Vienna Biocenter Association, explains,: "Biotechnology affects every one of us. I am glad that we are now able to impart the merits of the Campus Vienna Biocenter, located in the 3rd district, to 1.800.000 Viennese outside the Scientific Community."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.